205 results on '"E. Blyth"'
Search Results
52. Pulpwood Production in the Lake States, by County, 1979
53. Pulpwood Production in the Lake States by County, 1986
54. Fuelwood production and sources in Wisconsin, 1981
55. Michigan Saw Log Production and Sawmill Industry, 1978
56. Pulpwood Production in the Lake States by County, 1982
57. Veneer industry and timber use, North Central Region, 1980
58. Primary forest products industry and timber use, Michigan, 1977
59. Fuelwood production and sources from roundwood in Illinois, 1983
60. Pulpwood Production in the Lake States by County, 1988
61. Pulpwood Production in the Lake States by County, 1985
62. Primary forest products industry and timber use, Indiana, 1980
63. Pulpwood Production in the Lake States by County, 1984
64. Veneer-log production and receipts, North Central Region, 1974
65. Pulpwood production in the North Central Region, by county, 1980
66. Veneer industry and timber use, North Central Region, 1984
67. Primary forest products industry and timber use, Nebraska, 1980
68. Pulpwood production in the North Central Region by county, 1987
69. Pulpwood production in the North Central Region by County, 1983
70. Pulpwood production in the North Central Region by County, 1985
71. Primary forest products industry and timber use, Kansas, 1980
72. Pulpwood production in the north central region by county, 1978
73. Pulpwood Production in the Lake States by County, 1981
74. Pulpwood production in the north central region, by county, 1982
75. Indiana timber industry--an assessment of timber product output and use
76. Pulpwood production in the North Central Region by county, 1986
77. Illinois timber industry-an assessment of timber product output and use, 1983
78. Pulpwood Production in the Lake States by County, 1980
79. Pulpwood Production in the Lake States by County, 1983
80. Primary forest products industry and timber use, Iowa, 1980
81. Wisconsin timber industry--an assessment of timber product output and use
82. Pulpwood Production in the Lake States by County, 1987
83. Pulpwood production in the North Central Region, by county, 1981
84. [Physicians in Gothenburg during one hundred years]
85. Law governing the Connexion between the Number of Particles and their Diameters in grinding Crushed Sand
86. Samuel Wilderspin and the Infant School Movement
87. Agronomy and climatology of a 100 000 km² watershed in West Africa
88. Past and future spatio-temporal variability of rainfall of the Bani catchment in West Africa
89. Intra-tumoral and peripheral blood TIGIT and PD-1 as immune biomarkers in nodular lymphocyte predominant Hodgkin lymphoma.
90. Indeterminate measurable residual disease by multiparameter flow cytometry is associated with an intermediate risk of clinical relapse in adult patients with acute leukaemia.
91. Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study.
92. Circulating cytokine and chemokine patterns associated with cytomegalovirus reactivation after stem cell transplantation.
93. CAR + and CAR - T cells share a differentiation trajectory into an NK-like subset after CD19 CAR T cell infusion in patients with B cell malignancies.
94. Persistence of ex vivo expanded tumour and pathogen specific T-cells after allogeneic stem cell transplant for myeloid malignancies (the INTACT study).
95. Long-term outcomes of corticosteroid graft versus host disease prophylaxis in peripheral blood allogeneic haemopoietic stem cell transplant: a comparative cohort analysis.
96. Measurable Residual Disease (MRD) by Flow Cytometry in Adult B-Acute Lymphoblastic Leukaemia (B-ALL) and Acute Myeloid Leukaemia (AML): Correlation with Molecular MRD Testing and Clinical Outcome at One Year.
97. Australia and New Zealand Transplant and Cellular Therapies (ANZTCT) position statement: COVID-19 management in patients with haemopoietic stem cell transplant and chimeric antigen receptor T cell.
98. Combining CD34+ stem cell selection with prophylactic pathogen and leukemia directed T-cell immunotherapy to simultaneously reduce graft versus host disease, infection, and leukemia recurrence after allogeneic stem cell transplant.
99. Third-party CMV- and EBV-specific T-cells for first viral reactivation after allogeneic stem cell transplant.
100. Fitness criteria for Australian patients referred for chimeric antigen receptor T-cell therapy.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.